Biotech argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline July 27, 2026
Biotech Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28 July 25, 2026
Biotech Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm July 23, 2026
Biotech argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update July 23, 2026
Biotech Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom July 22, 2026